Abstract:Dear Editor, It was proposed by Haider and Ashraf1 that cytokine and growth factor mediated mobilization of endogenous mesenchymal stem cells from their bone marrow niches for homing into the infarcted myocardium could be a better therapeutic strategy than the explantation and subsequent injection of these cells (either autologous or from a donated allogenic source) directly into the damaged heart.2 Besides being less invasive to the patient, it was argued that this approach would obviate the need for ex vivo processing of the putative stem cells, which could in turn reduce the risk of nonspecific differentiation into undesired lineages at the transplantation site.3–5 Nevertheless, such an approach could be severely hampered by the age related decline in the regenerative capacity of the putative mesenchymal stem cell population within the bone marrow, as has been demonstrated by a number of studies.6,7 It must be remembered that the overwhelming majority of myocardial infarct cases occur in the older segment of the population.8 Quarto and colleagues6 demonstrated in a rat model that there was an age associated decline in the ability of marrow stromal cells to repair bone, which could be the underlying cause of age related osteodegenerative diseases. Subsequently, D’Ippolito and colleagues7 reported a similar finding with the human model. This would be expected because, with increasing age, the putative mesenchymal stem cell population within the bone marrow would have gone through more rounds of cell division, in addition to having been exposed to free radicals and metabolic toxins over a longer lifespan. Hence it is no surprise that there is a gradual decline in their regenerative capacity with increasing age. Although there have been no studies to date that have conclusively demonstrated an age associated decline in the capacity of bone marrow cells to repair the infarcted heart, we could make such a conjecture based upon extrapolation from the bone repair model.6,7 The obvious solution to overcome this age related decline in regenerative capacity would be to look at donated allogenic sources of stem cells for myocardial repair. In this regard, human embryonic stem (hES) cells or their differentiated progenies would hold much promise because these potentially represent an abundant and readily available source of transplantable cells. Recently, Zandstra and colleagues9 successfully developed a scalable, robust, and reproducible process for obtaining purified cardiomyocytes from hES cells. Nevertheless, the immunologic barrier10 probably represents the most formidable challenge to the allogenic transplantation of hES cells or their differentiated progenies into the infarcted myocardium. It is hoped that this could somehow be overcome in the near future. Boon Chin Heng* Eugene Kwang-Wei Sim† Tong Cao* *Stem Cell Laboratory, Faculty of Dentistry, †Department of Surgery, Faculty of Medicine National University of Singapore.

Mechanisms for Progenitor Cell-Mediated Repair for Ischemic Heart Injury

Reply to Letter from Drs. Haider and Ashraf

Homing of intravenously infused embryonic stem cell- derived cells to injured hearts after myocardial infarction

Role of Stem Cell Homing in Myocardial Regeneration

Transplantation of Hypoxia-Preconditioned Mesenchymal Stem Cells Improves Infarcted Heart Function Via Enhanced Survival of Implanted Cells and Angiogenesis

C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Stem Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function After Myocardial Infarction in a Paracrine Manner.

Potentiating the naturally occurring process for repair of damaged heart

Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction

Current Optimized Strategies for Stem Cell-Derived Extracellular Vesicle/exosomes in Cardiac Repair.

Cardiac Cell Therapy: Insights into the Mechanisms of Tissue Repair

Mesenchymal stem cell delivery strategies to promote cardiac regeneration following ischemic injury

Local Activation of Cardiac Stem Cells for Post-Myocardial Infarction Cardiac Repair

An acute immune response underlies the benefit of cardiac stem cell therapy

Repair Mechanisms of Bone Marrow Mesenchymal Stem Cells in Myocardial Infarction

Improving Cell Engraftment in Cardiac Stem Cell Therapy.

Comparative efficacy and mechanism of action of cardiac progenitor cells after cardiac injury

Cell survival and redistribution after transplantation into damaged myocardium.

Heart Regeneration by Endogenous Stem Cells and Cardiomyocyte Proliferation

Concise Review: Reduction of Adverse Cardiac Scarring Facilitates Pluripotent Stem Cell-Based Therapy for Myocardial Infarction

Mesenchymal Stem Cell Injection After Myocardial Infarction Improves Myocardial Compliance

Mesenchymal stem cell mediates cardiac repair through autocrine, paracrine and endocrine axes